WallStreetZenWallStreetZen

NASDAQ: SWAV
Shockwave Medical Inc Stock

$325.63+3.02 (+0.94%)
Updated Mar 28, 2024
SWAV Price
$325.63
Fair Value Price
-$237.02
Market Cap
$12.18B
52 Week Low
$157.00
52 Week High
$331.58
P/E
81.2x
P/B
18.21x
P/S
9.58x
PEG
4.76x
Dividend Yield
N/A
Revenue
$730.23M
Earnings
$147.28M
Gross Margin
86.9%
Operating Margin
24.81%
Profit Margin
20.2%
Debt to Equity
1.34
Operating Cash Flow
$196M
Beta
1.3
Next Earnings
May 6, 2024
Ex-Dividend
N/A
Next Dividend
N/A

SWAV Overview

ShockWave Medical, Inc., a medical device company, engages in developing and commercializing intravascular lithotripsy technology for the treatment of calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease (PAD); C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee PAD. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and sales managers, and distributors. The company was incorporated in 2009 and is headquartered in Santa Clara, California.

Zen Score

Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how SWAV scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

SWAV ($325.63) is overvalued by 237.39% relative to our estimate of its Fair Value price of -$237.02 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
SWAV ($325.63) is not significantly undervalued (237.39%) relative to our estimate of its Fair Value price of -$237.02 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
SWAV ($325.63) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more SWAV due diligence checks available for Premium users.

Be the first to know about important SWAV news, forecast changes, insider trades & much more!

SWAV News

Valuation

SWAV fair value

Fair Value of SWAV stock based on Discounted Cash Flow (DCF)
Price
$325.63
Fair Value
-$237.02
Undervalued by
237.39%
SWAV ($325.63) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SWAV ($325.63) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SWAV ($325.63) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

SWAV price to earnings (PE)

For valuing profitable companies with steady earnings
Company
81.2x
Industry
29.92x
Market
44.51x
SWAV is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
SWAV is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation

SWAV price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
18.21x
Industry
4.11x
SWAV is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

SWAV price to earnings growth (PEG)

For valuing profitable companies with growth potential
SWAV is poor value relative... subscribe to Premium to read more.
PEG Value Valuation

SWAV's financial health

Profit margin

Revenue
$203.0M
Net Income
$44.3M
Profit Margin
21.8%
SWAV's Earnings (EBIT) of $181.19M... subscribe to Premium to read more.
Interest Coverage Financials
SWAV's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$1.6B
Liabilities
$897.9M
Debt to equity
1.34
SWAV's short-term assets ($1.23B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SWAV's short-term assets ($1.23B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SWAV's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
SWAV's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$71.7M
Investing
-$242.3M
Financing
-$164.0k
SWAV's operating cash flow ($196.05M)... subscribe to Premium to read more.
Debt Coverage Financials

SWAV vs Medical Device Stocks

TickerMarket Cap1d %P/EP/B
SWAV$12.18B+0.94%81.20x18.21x
PODD$11.99B+1.31%57.91x16.36x
BRKR$12.93B+0.09%32.17x9.39x
SNN$11.13B-3.72%41.99x2.13x
BIO$9.86B-1.06%-15.85x1.13x

Shockwave Medical Stock FAQ

What is Shockwave Medical's quote symbol?

(NASDAQ: SWAV) Shockwave Medical trades on the NASDAQ under the ticker symbol SWAV. Shockwave Medical stock quotes can also be displayed as NASDAQ: SWAV.

If you're new to stock investing, here's how to buy Shockwave Medical stock.

What is the 52 week high and low for Shockwave Medical (NASDAQ: SWAV)?

(NASDAQ: SWAV) Shockwave Medical's 52-week high was $331.58, and its 52-week low was $157.00. It is currently -1.79% from its 52-week high and 107.41% from its 52-week low.

How much is Shockwave Medical stock worth today?

(NASDAQ: SWAV) Shockwave Medical currently has 37,396,816 outstanding shares. With Shockwave Medical stock trading at $325.63 per share, the total value of Shockwave Medical stock (market capitalization) is $12.18B.

Shockwave Medical stock was originally listed at a price of $30.50 in Mar 7, 2019. If you had invested in Shockwave Medical stock at $30.50, your return over the last 5 years would have been 967.64%, for an annualized return of 60.58% (not including any dividends or dividend reinvestments).

How much is Shockwave Medical's stock price per share?

(NASDAQ: SWAV) Shockwave Medical stock price per share is $325.63 today (as of Mar 28, 2024).

What is Shockwave Medical's Market Cap?

(NASDAQ: SWAV) Shockwave Medical's market cap is $12.18B, as of Mar 29, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Shockwave Medical's market cap is calculated by multiplying SWAV's current stock price of $325.63 by SWAV's total outstanding shares of 37,396,816.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.